Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy (Q39776358)

14 September 2017

title

Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy (English)

1 reference

14 September 2017

1 reference

Eftychia Lekka

1

1 reference

14 September 2017

Angelos D Gritzapis

2

1 reference

14 September 2017

Sonia A Perez

3

1 reference

14 September 2017

Nikolaos Tsavaris

4

1 reference

14 September 2017

Ioannis Missitzis

5

1 reference

14 September 2017

Avgi Mamalaki

6

1 reference

14 September 2017

Michael Papamichail

7

1 reference

14 September 2017

Constantin N Baxevanis

8

1 reference

14 September 2017

publication date

11 November 2009

1 reference

Cancer Immunology, Immunotherapy

14 September 2017

published in

1 reference

14 September 2017

volume

59

1 reference

14 September 2017

issue

5

1 reference

14 September 2017

page(s)

715-727

1 reference

Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00262-009-0791-7

IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-009-0791-7

Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-009-0791-7

Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-009-0791-7

Influence of CD4 CD25 regulatory T cells on low/high-avidity CD4 T cells following peptide vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-009-0791-7

Preferential in situ CD4 CD56 T cell activation and expansion within human glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-009-0791-7

Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-009-0791-7

Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4 regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00262-009-0791-7

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1084/JEM.178.2.489

Identifiers

DOI

10.1007/S00262-009-0791-7

1 reference

14 September 2017

1 reference